The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
about
HER3 as a Therapeutic Target in Cancer.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
P2860
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The anti-HER3 (ErbB3) therapeu ...... ependent ITCH/AIP4 activation.
@en
type
label
The anti-HER3 (ErbB3) therapeu ...... ependent ITCH/AIP4 activation.
@en
prefLabel
The anti-HER3 (ErbB3) therapeu ...... ependent ITCH/AIP4 activation.
@en
P2093
P2860
P356
P1433
P1476
The anti-HER3 (ErbB3) therapeu ...... ependent ITCH/AIP4 activation.
@en
P2093
Christel Larbouret
Christophe Le Clorennec
Gerry Melino
Marie-Alix Poul
Olivier Dubreuil
Philippe Mondon
Yassamine Lazrek
P2860
P304
37013-37029
P356
10.18632/ONCOTARGET.9455
P407
P577
2016-05-18T00:00:00Z